Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7379328 | 0.86 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL7374027 | 0.86 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL542283 | 0.85 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL30265157 | 0.84 | PRCP (0.44) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL5633667 | 0.84 | DPP4 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL9362980 | 0.84 | PRCP (0.44) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL7379008 | 0.83 | PRCP (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL10798003 | 0.83 | PRCP (0.37) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL146828 | 0.82 | NOS2 (0.46) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL995604 | 0.82 | NOS2 (0.46) | NOS2NOS3NOS1PRCPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41998-E1 | Compositions and methods of treatment of sympathetically maintained pain | Arclon Therapeutics, Inc. (US) | 2010-12-14 | — | — | US | claimed |
| US-6559186-B1 | Pain is treated topically by administering to the site where sympathetically maintained pain is present an alpha -1-adrenergic antagonist, alpha -2- adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic | ARC 1, INC. | 2003-05-06 | — | — | US | claimed |
| US-RE41998-E1 | Compositions and methods of treatment of sympathetically maintained pain | Arclon Therapeutics, Inc. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | disclosed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | disclosed |
| US-6559186-B1 | Pain is treated topically by administering to the site where sympathetically maintained pain is present an alpha -1-adrenergic antagonist, alpha -2- adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic | ARC 1, INC. | 2003-05-06 | — | — | US | disclosed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | disclosed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | disclosed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | disclosed |
| EP-0017390-A2 | Bicyclic oxo-thiolactones, pharmaceutical compositions containing them, processes for their preparation and compounds useful as intermediates for their preparation | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-10-15 | — | — | EP | disclosed |
| WO-1980002025-A1 | BICYCLIC OXO-THIOLACTONES | AMERICAN HOME PROD (US) | 1980-10-02 | — | — | WO | disclosed |
| US-4179568-A | (N-lower alkyl-3,5-dioxo-3-pyrrolidinyl)thioalkanoylpyrrolidine-and piperidine-carboxylic acid compounds | E. R. SQUIBB & SONS, INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4154840-A | Antihypertensive pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4105776-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4046889-A | HYPOTENSIVE AGENTS, ENZYME INHIBITORS, ANGIOTENSIN CONVERSION | E. R. SQUIBB & SONS, INC. (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | NOS2 1242/4885NOS3 1167/4885NOS1 844/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | NOS2 965/4885NOS3 728/4885NOS1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.